Braveheart Bio Reports Third Quarter 2026 Financial Results
Braveheart Bio, Inc. reported its unaudited financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline.
Stocks · News reference
Braveheart Bio, Inc. reported long-term efficacy and safety data from a 52-week open-label extension study of its lead candidate, BHB-1893, at the American Heart Association Scientific Sessions 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Braveheart Bio, Inc. reported its unaudited financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline.
Braveheart Bio, Inc. announced its participation in the upcoming Jefferies Global Healthcare Conference in London, where management will host a fireside chat.
Filed: 2026-11-06 AccNo: 0001628280-26-071586 Size: 302 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Braveheart Bio, Inc. will present late-breaking 52-week extension data for its cardiac myosin inhibitor, BHB-1893, at the American Heart Association Scientific Sessions 2026 and host a related investor webinar.
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Braveheart Bio (NASDAQ:BRVE) with a Overweight and maintains $40 price target.